Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 6/20 | 0.44 |
| ▸ | JAK2 | O60674 | 9/20 | 0.43 |
| ▸ | JAK1 | P23458 | 6/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 2/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CCNK | O75909 | 1/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | CCND3 | P30281 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2694968 | 0.89 | SYK (0.47) | PTPN11JAK3JAK2JAK1SYK | |
| SCHEMBL4403366 | 0.85 | JAK3 (0.47) | JAK3JAK2JAK1SYKTYK2 | |
| SCHEMBL2695976 | 0.84 | MAPK10 (0.51) | JAK3JAK2JAK1SYKTYK2 | |
| SCHEMBL2697251 | 0.84 | JAK3 (0.46) | JAK3JAK2JAK1SYKTYK2 | |
| SCHEMBL2695144 | 0.81 | SYK (0.54) | SYK | |
| SCHEMBL2695387 | 0.79 | SYK (0.52) | JAK3JAK2JAK1SYKTYK2 | |
| SCHEMBL2693764 | 0.78 | WNT3A (0.48) | JAK3SYK | |
| SCHEMBL4404194 | 0.77 | STAT6 (0.50) | JAK3JAK2JAK1SYKTYK2 | |
| SCHEMBL2695389 | 0.76 | JAK3 (0.53) | JAK3JAK2JAK1PIK3CATYK2 | |
| SCHEMBL2695768 | 0.76 | MAPK10 (0.58) | JAK3JAK2JAK1SYKTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2975027-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | Portola Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9102625-B2 | Nicotinamides as JAK kinase modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| WO-2012061428-A2 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | PTPN11 159/4885JAK3 4/4885JAK2 1/4885 |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | PTPN11 159/4885JAK3 4/4885JAK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.